Med. praxi. 2026;23(3):211-214 | DOI: 10.36290/med.2026.011

Antihypertensive drugs and their drug interactions in general practice

MUDr. Karel Lábr, Ph.D., MUDr. Monika Špinarová, Ph.D.
I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně

Drug interactions are a frequent and clinically important cause of poor blood pressure control, adverse effects of antihypertensive treatment and worsening kidney function. In general practice, it is important to consider not only interactions among antihypertensive agents themselves, but also commonly used prescription and over-the-counter drugs that may increase blood pressure or reduce treatment efficacy. The most relevant examples include non-steroidal anti-inflammatory drugs, nasal decongestants with sympathomimetic activity, selected antidepressants, glucocorticoids and hormonal therapy. Particularly important are combinations of renin-angiotensin system inhibitors with other drugs increasing the risk of hyperkalaemia or acute kidney injury, and combinations of beta-blockers with verapamil or diltiazem. Less obvious but clinically relevant pharmacokinetic interactions also involve patiromer, sodium zirconium cyclosilicate, cholestyramine, iron salts, lithium, digoxin and direct oral anticoagulants. The aim of this review is to provide a practical overview of the most important antihypertensive drug interactions, highlight high-risk situations in routine outpatient care and summarize the basic principles of monitoring and prevention.

Keywords: hypertension, antihypertensive drugs, drug interactions, primary care, adverse effects.

Received: March 30, 2026; Accepted: March 30, 2026; Published: June 22, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lábr K, Špinarová M. Antihypertensive drugs and their drug interactions in general practice. Med. praxi. 2026;23(3):211-214. doi: 10.36290/med.2026.011.
Download citation

References

  1. Mancia G, Kreutz R, Brunstrom M, et al. 2023 ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension. J Hypertens. 2023;41:1874-2071. Go to original source... Go to PubMed...
  2. Kreutz R, Brunstrom M, Burnier M, et al. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med. 2024;126:1-15. Go to original source... Go to PubMed...
  3. Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults. Circulation. 2025;152:e114-e218. Go to original source... Go to PubMed...
  4. Fravel MA, Ernst ME. Drug interactions with antihypertensives. Curr Hypertens Rep. 2021;23:14. Go to original source... Go to PubMed...
  5. Carter BL, Lund BC, Hayase N, et al. A longitudinal analysis of antihypertensive drug interactions in a Medicaid population. Am J Hypertens. 2004;17(5 Pt 1):421-7. Go to original source... Go to PubMed...
  6. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59. Go to original source... Go to PubMed...
  7. Parving HH, Brenner BM, McMurray JJV, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204-13. Go to original source... Go to PubMed...
  8. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892-903. Go to original source... Go to PubMed...
  9. Silva AR, Martini AG, Canto GDL, et al. Effects of dual blockade in heart failure and renal dysfunction: systematic review and meta-analysis. J Renin Angiotensin Aldosterone Syst. 2019;20:1470320319882656. Go to original source... Go to PubMed...
  10. Valdivielso JM, Balafa O, Ekart R, et al. Hyperkalemia in chronic kidney disease in the new era of kidney protection therapies. Drugs. 2021;81:1467-89. Go to original source... Go to PubMed...
  11. Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169:1156-62. Go to original source... Go to PubMed...
  12. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160:685-93. Go to original source... Go to PubMed...
  13. Holtkamp FA, de Zeeuw D, Thomas MC, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 2011;80:282-7. Go to original source... Go to PubMed...
  14. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80:565-81. Go to original source... Go to PubMed...
  15. Wiggins BS, Dixon DL, Neyens RR, et al. Select drug-drug interactions with direct oral anticoagulants. J Am Coll Cardiol. 2020;75:1341-50. Go to original source... Go to PubMed...
  16. Takara K, Kakumoto M, Tanigawara Y, et al. Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002;70:1491-500. Go to original source... Go to PubMed...
  17. Finley PR, O'Brien JG, Coleman RW. Lithium and angiotensin-converting enzyme inhibitors: evaluation of a potential interaction. J Clin Psychopharmacol. 1996;16:68-71. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.